Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF)

Circulation

Volumn 133, Issue 23, 2016, Pages 2254-2262

  Okumura, Naoki ^a   Jhund, Pardeep S ^a   Gong, Jianjian ^b   Lefkowitz, Martin P ^b   Rizkala, Adel R ^b   Rouleau, Jean L ^c   Shi, Victor C ^b   Swedberg, Karl ^d,e   Zile, Michael R ^f   Solomon, Scott D ^g   Packer, Milton ^h   McMurray, John J V ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

^c MONTREAL HEART INSTITUTE   (Canada)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

emergency service, hospital; heart failure; hospitalization; mortality; neprilysin; sacubitril valsartan

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGITALIS; DIGOXIN; DIURETIC AGENT; ENALAPRIL; MINERALOCORTICOID ANTAGONIST; SACUBITRIL PLUS VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MEMBRANE METALLOENDOPEPTIDASE; PROTEINASE INHIBITOR; TETRAZOLE DERIVATIVE;

ADULT; ARTICLE; ATRIAL FIBRILLATION; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; EMERGENCY CARE; FEMALE; HEART FAILURE; HEART INFARCTION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; AGED; AMBULATORY CARE; ANTAGONISTS AND INHIBITORS; BIOASSAY; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE COURSE; METABOLISM; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOPHYSIOLOGY; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

AGED; AMBULATORY CARE; AMINOBUTYRATES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; ENALAPRIL; ENDPOINT DETERMINATION; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NEPRILYSIN; PROSPECTIVE STUDIES; PROTEASE INHIBITORS; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84964206619     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.115.020729     Document Type: Article

References (21)

1. Solomon SD, Dobson J, Pocock S, Skali H, McMurray JJ, Granger CB, Yusuf S, Swedberg K, Young JB, Michelson EL, Pfeffer MA; Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Investigators. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation. 2007;116:1482-1487. doi: 10.1161/CIRCULATIONAHA.107.696906.
2. Ahmed A, Allman RM, Fonarow GC, Love TE, Zannad F, Dell'italia LJ, White M, Gheorghiade M. Incident heart failure hospitalization and subsequent mortality in chronic heart failure: a propensity-matched study. J Card Fail. 2008;14:211-218. doi: 10.1016/j. cardfail.2007.12.001.
3. McMurray JJ, Petrie MC, Murdoch DR, Davie AP. Clinical epidemiology of heart failure: public and private health burden. Eur Heart J. 1998;19(suppl P):P9-16.
4. Stewart S, Jenkins A, Buchan S, McGuire A, Capewell S, McMurray JJ. The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail. 2002;4:361-371.
5. Zannad F, Garcia AA, Anker SD, Armstrong PW, Calvo G, Cleland JG, Cohn JN, Dickstein K, Domanski MJ, Ekman I, Filippatos GS, Gheorghiade M, Hernandez AF, Jaarsma T, Koglin J, Konstam M, Kupfer S, Maggioni AP, Mebazaa A, Metra M, Nowack C, Pieske B, Piña IL, Pocock SJ, Ponikowski P, Rosano G, Ruilope LM, Ruschitzka F, Severin T, Solomon S, Stein K, Stockbridge NL, Stough WG, Swedberg K, Tavazzi L, Voors AA, Wasserman SM, Woehrle H, Zalewski A, McMurray JJ. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. Eur J Heart Fail. 2013;15:1082-1094. doi: 10.1093/eurjhf/hft095.
6. Suter LG, Li SX, Grady JN, Lin Z, Wang Y, Bhat KR, Turkmani D, Spivack SB, Lindenauer PK, Merrill AR, Drye EE, Krumholz HM, Bernheim SM. National patterns of risk-standardized mortality and readmission after hospitalization for acute myocardial infarction, heart failure, and pneumonia: update on publicly reported outcomes measures based on the 2013 release. J Gen Intern Med. 2014;29:1333-1340. doi: 10.1007/s11606-014-2862-5.
7. Vidic A, Chibnall JT, Hauptman PJ. Heart failure is a major contributor to hospital readmission penalties. J Card Fail. 2015;21:134-137. doi: 10.1016/j.cardfail.2014.12.002.
8. Huesch MD, Ong MK, Fonarow GC. Measuring heart failure care by 30-day readmission: rethinking the quality of outcome measures. Am Heart J. 2013;166:605-610.e2. doi: 10.1016/j.ahj.2013.07.026.
9. Kociol RD, Liang L, Hernandez AF, Curtis LH, Heidenreich PA, Yancy CW, Fonarow GC, Peterson ED. Are we targeting the right metric for heart failure? Comparison of hospital 30-day readmission rates and total episode of care inpatient days. Am Heart J. 2013;165:987-994.e1. doi: 10.1016/j.ahj.2013.02.006.
10. Ezekowitz JA, Kaul P, Bakal JA, Quan H, McAlister FA. Trends in heart failure care: has the incident diagnosis of heart failure shifted from the hospital to the emergency department and outpatient clinics? Eur J Heart Fail. 2011;13:142-147. doi: 10.1093/eurjhf/hfq185.
11. Shafazand M, Patel H, Ekman I, Swedberg K, Schaufelberger M. Patients with worsening chronic heart failure who present to a hospital emergency department require hospital care. BMC Res Notes. 2012;5:132. doi: 10.1186/1756-0500-5-132.
12. Brar S, McAlister FA, Youngson E, Rowe BH. Do outcomes for patients with heart failure vary by emergency department volume? Circ Heart Fail. 2013;6:1147-1154. doi: 10.1161/CIRCHEARTFAILURE. 113.000415.
13. Blecker S, Ladapo JA, Doran KM, Goldfeld KS, Katz S. Emergency department visits for heart failure and subsequent hospitalization or observation unit admission. Am Heart J. 2014;168:901-8.e1. doi: 10.1016/j. ahj.2014.08.002.
14. Sperry BW, Ruiz G, Najjar SS. Hospital readmission in heart failure, a novel analysis of a longstanding problem. Heart Fail Rev. 2015;20:251-258. doi: 10.1007/s10741-014-9459-2.
15. Skali H, Dwyer EM, Goldstein R, Haigney M, Krone R, Kukin M, Lichstein E, McNitt S, Moss AJ, Pfeffer MA, Solomon SD. Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT-CRT. Eur J Heart Fail. 2014;16:560-565. doi: 10.1002/ejhf.71.
16. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau J, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Committees and Investigators. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2013;15:1062-1073. doi: 10.1093/eurjhf/hft052.
17. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004. doi: 10.1056/NEJMoa1409077.
18. Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile M, Andersen K, Arango JL, Arnold JM, Bělohlávek J, Böhm M, Boytsov S, Burgess LJ, Cabrera W, Calvo C, Chen CH, Dukat A, Duarte YC, Erglis A, Fu M, Gomez E, Gonzàlez-Medina A, Hagège AA, Huang J, Katova T, Kiatchoosakun S, Kim KS, Kozan Ö, Llamas EB, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires FJ, Refsgaard J, Rosenthal A, Senni M, Sibulo AS Jr, Silva-Cardoso J, Squire IB, Starling RC, Teerlink JR, Vanhaecke J, Vinereanu D, Wong RC; PARADIGM-HF Investigators and Coordinators. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131:54-61. doi: 10.1161/CIRCULATIONAHA.114.013748.
19. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675. doi: 10.1056/NEJMoa010713.
20. Curtis AB, Worley SJ, Adamson PB, Chung ES, Niazi I, Sherfesee L, Shinn T, Sutton MS; Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block (BLOCK HF) Trial Investigators. Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med. 2013;368:1585-1593. doi: 10.1056/NEJMoa1210356.
21. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140-2150. doi: 10.1056/NEJMoa032423.